Progesterone Preeclampsia
This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal…
Conditions studied
Preeclampsia, Hypertensive Disorder of Pregnancy
About this study
This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.
Interventions
- Drug: Progesterone supplementation — Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.
Primary outcomes
- Development of preeclampsia (Antenatally and up to 6 weeks postpartum)
Eligibility information
Study locations
- Medical University of South Carolina, Charleston, South Carolina 29401 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-03.